13211-32-0

Basic information

• Product Name: TERT-BUTOXY ACETIC ACID
• Synonyms: O-TERT-BUTYL-GLYCOLLIC ACID;TERT-BUTOXY ACETIC ACID;2-TERT-BUTOXYACETIC ACID;2-TERTIARY-BUTOXYACETIC ACID;2-tert-Butoxyacetic;(tert-Butoxy)ethanoic acid;Acetic acid,2-(1,1-dimethylethoxy)-
• CAS NO: 13211-32-0
• Molecular Formula: C₆H₁₂O₃
• Molecular Weight: 132.16
• Product Categories: Small molecule
• Mol File: 13211-32-0.mol
• Article Data: 14

Chemical Properties

• Melting Point: -5 °C
• Boiling Point: 222.286 °C at 760 mmHg
• Flash Point: 88.545 °C
• Appearance: /
• Density: 1.028 g/cm³
• Vapor Pressure: 0.038mmHg at 25°C
• Refractive Index: 1.428
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.55±0.10(Predicted)
• CAS DataBase Reference: TERT-BUTOXY ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: TERT-BUTOXY ACETIC ACID(13211-32-0)
• EPA Substance Registry System: TERT-BUTOXY ACETIC ACID(13211-32-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 13211-32-0(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Tetrahedron Letters, 24, p. 3165, 1983 DOI: 10.1016/S0040-4039(00)88125-3

InChI:InChI=1/C6H12O3/c1-6(2,3)9-4-5(7)8/h4H2,1-3H3,(H,7,8)

Upstream product

• 79-08-3 bromoacetic acid 
• 75-65-0 tert-butyl alcohol 
• 42415-65-6 tert-butoxy-acetic acid ethyl ester 
• 865-47-4 potassium tert-butylate 
• 79-11-8 chloroacetic acid 
• 1907-33-1 lithium tert-butoxide 
• 68470-79-1 trans-2,3-di(tert-butoxy)-1,4-dioxane 
• 78968-64-6 meso-1,2-di-t-butoxy-1,2-dimethoxyethane 
• 70525-97-2 (E)-1-bromo-1,2-di-tert-butoxy-ethene 
• 70525-93-8 (E)-1,2-bis(tert-butoxy)-1-chloroethene 
• 68470-81-5 meso-1,2-di-tert-butoxy-1,2-dichloroethane 
• 94045-49-5 1,2-di-tert-butoxyethene 
• 137676-99-4 2-(1,1-dimethylethoxy)acetic acid methyl ester 
• 66478-63-5 1,2-bis(tert-butoxy)acetylene 

Downstream Products

• 6403-40-3 tert-Butoxy-essigsaeure-cyanmethylester 
• 116193-69-2 3,5-bis(2-tert-butoxyacetamido)nitrobenzene 
• 67354-35-2 ethyl 4-(tert-butoxy)-3-oxobutanoate 
• 1591827-24-5 3-((1-((5-(tert-butoxymethyl)-6-methoxypyridazin-3-yl)methyl)-6-oxo-4-(trifluoro methyl)-1,6-dihydropyrimidin-5-yl)oxy)-5-chlorobenzonitrile 
• 1542225-28-4 3-(tert-butoxymethyl)-1-phenylpyrrolidine-2,5-dione 
• 1427265-07-3 3-[5-(2-tert-butoxyacetyl)-1-(2,4-difluorobenzyl)-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridin-3-yl]benzonitrile 
• 137676-99-4 2-(1,1-dimethylethoxy)acetic acid methyl ester 
• 78890-64-9 (2R,3R,4S,5R,6S)-3,4,5-Tris-benzyloxy-2-benzyloxymethyl-6-(2-tert-butoxy-ethoxy)-tetrahydro-pyran 
• 15913-59-4 N-(O-tert.Butylglykolyl)-L-alanin-p-nitrobenzylester 
• 6377-28-2 p-nitrophenyl tert-butyloxyacetate 

Relevant articles and documents

2-(4-CHLOROPHENOXY)-N-((1 -(2-(4-CHLOROPHENOXY)ETHYNAZETIDIN-3-YL)METHYL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES

The invention is directed to substituted azetidine derivatives. Specifically, the invention is directed to compounds according Formula I: (I) wherein C, D, L1,L2,L3,R1, R2, R4, R5, R6, z2, z4, z5, and z6are as defined herein; and salts thereof. The invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to compounds for use in methods of inhibiting the ATF4 (activating transcription factor 4) pathway and treatment of disorders associated therewith, such as e.g. cancer, neurodegenerative diseases and many other diseases, using a compound of the invention or a pharmaceutical composition comprising a compound of the invention. Preferred compounds of the invention are 2-(4-chlorophenoxy)-N-((l- (2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds.

PROCESS FOR THE PREPARATION OF A GLUCOKINASE ACTIVATOR COMPOUND

The present invention relates to a process for the preparation of a compound of formula I, wherein R1 is C1-6-alkyl and R2 is hydrogen or halogen. (R)-2-phenyl propionic acid derivatives of formula I are key intermediates in the synthesis of 5-substituted-pyrazine or pyridine glucokinase activators of the formula Xa, which have the potential to be useful for the treatment and/or prophylaxis of type II diabetes.

2-Arylbenzoxazoles as CETP inhibitors: Substitution and modification of the α-alkoxyamide moiety

The development of a series of 2-arylbenzoxazole α-alkoxyamide and β-alkoxyamine inhibitors of cholesteryl ester transfer protein (CETP) is described. Highly fluorinated α-alkoxyamides proved to be potent inhibitors of CETP in vitro, and the highly fluorinated 2-arylbenzoxazole β-alkoxyamine 4 showed a desirable combination of in vitro potency (IC50 = 151 nM) and oral bioavailability in the mouse.